× Key messages Background The study Conclusions Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Conclusions

  • Ertugliflozin is noninferior to placebo for reducing CV events in patients with T2D and established CVD.
  • Trends were noted for a beneficial effect on renal outcomes, although this was not statistically significant.
  • The safety profile was consistent with the established profile of SGLT2 inhibitors.